Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals, Inc TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash…